Navigation Links
Medtronic Infuse Bone Graft Lawsuits: Bernstein Liebhard LLP Notes New Report Predicting Hundreds of Medtronic Infuse Lawsuits
Date:4/6/2013

New York, New York (PRWEB) April 06, 2013

The Medtronic Infuse lawyers at Bernstein Liebhard LLP note that a new report published by MassDevice.com predicts that hundreds of Medtronic Infuse Bone Graft lawsuits could ultimately be filed by individuals who allegedly suffered serious complications due to the controversial bone growth protein. According to the report, a Medtronic Infuse lawsuit was recently filed in U.S. District Court, Southern District of Ohio, involving 88 patients who allegedly received the bone protein in experimental spine surgeries without their consent. In addition to Medtronic Inc., the lawsuit names the Ohio surgeon who performed the surgeries and was a paid consultant to Medtronic. According to court documents, all of the plaintiffs allege the doctor “performed medically unnecessary, experimental spines surgeries on plaintiffs using falsely and improperly marketed Medtronic medical devices and drugs." (Case No. 1:13-cv-00202-SSB). *

“Considering all of the controversies that have erupted over the years regarding this product, it would not be surprising to see a large number of Medtronic Infuse lawsuit filings,” says Bernstein Liebhard LLP, a nationwide law firm currently evaluating Medtronic Infuse Bone Graft lawsuits on behalf of individuals who may have suffered respiratory problems, nerve damage, and wrongful death, allegedly associated with use of Infuse.

Medtronic Infuse Complications
Medtronic Infuse Bone Graft was approved by the U.S. Food & Drug Administration (FDA) in 2002 for stimulating spinal bone growth in patients with a degenerative disease affecting the lower spine. In 2008, the FDA warned that Infuse Bone Graft had been associated with serious complications when used off-label in cervical spine fusions, including excessive swelling in the neck, compressed airways, difficulty breathing, problems swallowing and nerve damage.**

Since the FDA warning, Medtronic Infuse has been the subject of growing controversy, some of which have raised questions about Medtronic's financial relationships with doctors, according to Bernstein Liebhard. This past October, a U.S. Senate Finance Committee report raised disturbing questions about the research used to back Infuse. The report found that Medtronic paid out $210 million in royalties, consulting fees, and other payments to the doctors who co-authored the Medtronic-sponsored Infuse studies. Among other things, Senate investigators charged that Medtronic deliberately manipulated the studies to downplay Infuse side effects and promote off-label use of the product.***

In 2011, The Spine Journal raised similar questions when it dedicated an entire issue to studying the risks of the recombinant bone morphogenetic protein-2, or BMP-2, used in Medtronic Infuse Bone Graft. The journal’s investigation found that more than a dozen Medtronic-funded studies downplayed or entirely omitted evidence of safety issues associated with Infuse.****

The Medtronic Infuse lawyers at Bernstein Liebhard LLP are offering free lawsuit consultations to anyone allegedly injured by Medtronic Infuse Bone Graft. Victims of serious Infuse complications may be entitled to compensation for their medical care, pain and suffering, and other damages. A wealth of information regarding Medtronic Infuse Bone Graft lawsuits is available on the Firm’s website. For more information about Medtronic Infuse lawsuits, please contact one of our attorneys by calling 877-779-1414.

*massdevice.com/news/lawyer-foresees-100s-more-claims-against-medtronic-infuse-lawsuits-massdevicecom-call
**fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062000.htm
***finance.senate.gov/newsroom/chairman/release/?id=b1d112cb-230f-4c2e-ae55-13550074fe86
**** thespinejournalonline.com/article/S1529-9430%2811%2900299-3/abstract

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/medtronic-infuse-lawsuit/medtronic-infuse-injuries/prweb10606546.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Medtronic Infuse Bone Graft Questioned As Allegations Unfold – Bisnar
2. Chase Attorneys Offer Free Consultations
3. Medtronic Voted the Most Sought-After Employer by MedReps.com Community
4. Medtronic Infuse bone-graft lawsuit consultation referrals offered by Resource4thePeople
5. 2013 Cases Involving Medtronic Infuse Bone Graft Failure Allegations Now Being Investigated by Resource4thePeople Lawyers
6. Fish Oil Doesnt Cut Failure Rate of Hemodialysis Grafts
7. Donor aortic graft improves reconstruction after partial laryngectomy
8. Miami Children’s Hospital Performs First Nerve Repair Surgery Using Avance® Nerve Graft Technology
9. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
10. HIV drug reduces graft-vs.-host disease in bone marrow transplant patients, Penn study shows
11. Blood condition is highly predictive of graft failure in pediatric kidney transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
(Date:4/24/2017)... ... April 24, 2017 , ... In ... be diagnosed globally; approximately 25,000 of them will be malignant.(1) As research into ... this type of healthcare model in the diagnosis and treatment of brain tumors. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant ... website. , Rod has been at the forefront of Gardant since it was founded ... Rod has overseen the opening of more than 40 new senior living communities. With ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for her ... good news for single women is that she put all the words in her ... 25th. Joan's insight, personal experiences and sparkling sense of humor have inspired her to ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... familiar. This makes it difficult for lab operators and management to assess these ... help them identify wasteful or unnecessary actions. , Created with the help ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: